Item 5. Other Information
ITEM
5: Other Information
On
May 13, 2021, we completed our re-purchase of our New Brunswick, New Jersey facility pursuant to the repurchase option in the
facility lease for $4,661,400.
ITEM
6: Exhibits
(a)
Exhibits
10.1
April 19, 2021 Purchase and Sale Agreement with Phoenix Equipment Corporation, Branford Auctions, LLC and Perry Videx LLC .*
10.2
Material Transfer and Research agreement with Roswell Park Comprehensive Cancer Center executed on April 14, 2021 (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)).*
10.3
May 1, 2021 extension of April 1, 2020 Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited.*
10.4
Material Transfer And Research Agreement with the University of Cagliari Dipartimento di Scienze della Vita e dell’Ambiente executed on April 5, 2021 (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)).*
10.5
May 12, 2021 Amendment to the Renewed Sales, Marketing, Distribution and Supply Agreement with GPPharm. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10))*
10.6
January 11, 2021 Sponsor Agreement with Centre for Human Drug Research. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10))**
10.7
March 24, 2021 employment agreement with Peter Rodino.**
10.8
March 24, 2021 employment agreement with Ellen Lintal.**
31.1
Certification
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.*
31.2
Certification
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.*
32.1
Certification
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.*
32.2
Certification
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.*
38
101.INS
XBRL
Instance Document * ***
101.SCH
XBRL
Taxonomy Extension Schema Document * ***
101.CAL
XBRL
Taxonomy Extension Calculation Linkbase Document * ***
101.DEF
XBRL
Taxonomy Extension Definition Linkbase Document * ***
101.LAB
XBRL
Taxonomy Extension Label Linkbase Document * ***
101.PRE
XBRL
Taxonomy Extension Presentation Linkbase Document * ***
*
Filed herewith.
**
Filed with the Securities and Exchange Commission as an exhibit to the Company’s Annual Report on Form 10-K for the year ended
December 31, 2020 filed March 31, 2021 and is hereby incorporated by reference.
***
Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus
for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities and Exchange Act of 1934,
as amended and otherwise are not subject to liability under those sections.
39
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
AIM
IMMUNOTECH INC.
/s/
Thomas K. Equels
Thomas
K. Equels, Esq.
Chief
Executive Officer & President
/s/
Ellen M. Lintal
Ellen
M. Lintal
Chief
Financial Officer
Date:
May 17, 2021
40